# US 11,998,515 B1 · Enhancement of curcumin plasma levels using eucalyptol co-administration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,998,515 B1
- Document ID: US11998515B1
- Status: Granted
- Kind: B1
- Application number: 18/237,710
- Filed: 2023-08-24
- Granted: 2024-06-04
- Earliest claimed: 2023-04-24
- Assignees: King Faisal University
- Applicants: King Faisal University
- Inventors: Maged Elsayed Mohamed; Nancy Safwat Younis
- Web page: https://patentgrep.com/patent/US11998515B1

## CPC

- A61K 31/12: Ketones
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 47/38: Cellulose; Derivatives thereof
- A61K 47/02: Inorganic compounds
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Compositions and methods for co-administering curcumin and eucalyptol to a subject. Through the combined administration with eucalyptol, the plasma levels of curcumin will increase over the current baseline, thereby increasing the medicinal activity of the polyphenol and contributing to the reduction of an effective dose thereof, thereby also decreasing the incidence of side effects.

## Claims

### Claim 1

A method of increasing curcumin plasma levels in a subject, the method comprising:
orally administering a composition to a subject in need thereof, wherein the composition comprises:
about 10 mg of curcumin per kg of body weight in a subject to which the composition is administered;
about 5 mg to about 20 mg of eucalyptol per kg of body weight in the subject to which the composition is administered; and
an orally acceptable carrier that is saline;
wherein the curcumin and the eucalyptol are solubilized in carboxy methyl cellulose; and
wherein the curcumin and the eucalyptol are co-administered to the subject, wherein the curcumin plasma levels in the subject increased by 6-9 times from baseline plasma levels of curcumin in a subject who is untreated with the composition following oral administration of the composition to the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein about 10 to about 20 mg of the eucalyptol are administered per 1 kg of body weight of the subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the curcumin plasma level in the subject increases about 1 hour following oral administration of the composition to the subject.

### Claim 4 (depends on 1)

The method of claim 1, wherein the curcumin plasma level in the subject reaches a maximum concentration about 4 hours following oral administration of the composition to the subject.

### Claim 5 (depends on 1)

The method of claim 1, wherein the curcumin plasma level in the subject reaches a maximum concentration in about 33% less time following oral administration of the composition to the subject when compared to administration of a composition consisting of curcumin to the subject.

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition is administered to the subject for at least ten days.